Drug Trial Radar · NCT03902184
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
May 22, 2019
Primary completion
Jan 8, 2026
Study completion Jan 8, 2026
Sponsor
- Lead sponsor
- Innate PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Conditions
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides/Sezary Syndrome
Interventions
IPH4102Biological
Patients will receive a flat dose of 750mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From the first dose until study completion, an expected average of 2 years
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California
Irvine Medical Center
Orange, California
Stanford University
Stanford, California
Moffitt Cancer Center
Tampa, Florida
University of South Florida
Tampa, Florida
Northwestern University The Feinberg School of Medicine
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Universal Dermatology, PLLC68
Fairport, New York
Columbia University Department of Dermatology
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Inova Health Care Services
Fairfax, Virginia
Universitätsklinik für Dermatologie Medizinische Universität Graz
Graz, Austria
Medizinische Universitaet Wien
Vienna, Austria
Institut Jules Bordet
Brussels, Belgium
UZ Leuven - campus Gasthuisberg
Leuven, Belgium
Centre Hospitalier Universitaire (CHU) de Liege
Liège, Belgium
CHU de Bordeaux Saint André
Bordeaux, France
CHRU de Tours, Hôpital Trousseau
Chambray-lès-Tours, France
CHU Henri Mondor
Créteil, France
CHRU de Lille - Hopital Claude Huriez
Lille, France
Centre Hospitalier Lyon-Sud
Lyon, France
Institut Paoli-Calmettes
Marseille, France
CHRU de Montpellier - Hopital Saint Eloi
Montpellier, France
Hôpital Saint-Louis
Paris, France
Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie
Rouen, France
IUCT Oncopôle
Toulouse, France
Charite - Universitaetsmedizin Berlin
Berlin, Germany
Ruhr-University Bochum
Bochum, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Universitaetsklinikum Halle (Saale)
Halle, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany
Universitaetsmedizin Mannheim GmbH
Mannheim, Germany
Johannes Wesling Klinikum Minden
Minden, Germany
Universitaetsklinikum Muenster
Münster, Germany
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.